The STATs of cancer — new molecular targets come of age (original) (raw)
Bishop, J. M. The molecular genetics of cancer. Science235, 305–311 (1987). CASPubMed Google Scholar
Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet.9, 138–141 (1993). CASPubMed Google Scholar
Hahn, W. C. & Weinberg, R. A. Rules for making human tumor cells. New England J. Med.347, 1593–1603 (2002). CAS Google Scholar
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science296, 1655–1657 (2002). CASPubMed Google Scholar
Darnell, J. E. Jr Transcription factors as targets for cancer therapy. Nature Rev. Cancer2, 740–749 (2002). Superb review that makes a persuasive case for targeting transcription factors for cancer therapy. CAS Google Scholar
Egan, S. E. & Weinberg, R. A. The pathway to signal achievement. Nature365, 781–783 (1993). CASPubMed Google Scholar
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nature Rev. Cancer2, 489–501 (2002). CAS Google Scholar
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell100, 57–70 (2000). CASPubMed Google Scholar
Darnell, J. E. Jr, Kerr, I. M. & Stark, G. R. Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science264, 1415–1421 (1994). CASPubMed Google Scholar
Darnell, J. E. Jr STATs and gene regulation. Science277, 1630–1635 (1997). CASPubMed Google Scholar
Bromberg, J. & Darnell, J. E. Jr The role of STATs in transcriptional control and their impact on cellular function. Oncogene19, 2468–2473 (2000). CASPubMed Google Scholar
Bowman, T., Garcia, R., Turkson, J. & Jove, R. STATs in oncogenesis. Oncogene19, 2474–2488 (2000). CASPubMed Google Scholar
Darnell, J. E. Jr Studies of IFN-induced transcriptional activation uncover the Jak–Stat pathway. Interferon Cytokine Res.18, 549–554 (1998). CAS Google Scholar
Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem.67, 227–264 (1998). CASPubMed Google Scholar
Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther.82, 231–239 (1999). CASPubMed Google Scholar
Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research. Science287, 1969–1973 (2000). CASPubMed Google Scholar
Buettner, R., Mora, L. B. & Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res.8, 945–954 (2002). CASPubMed Google Scholar
Taga, T. & Kishimoto, T. gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol.15, 797–819 (1997). CASPubMed Google Scholar
Ihle, J. N. The Stat family in cytokine signaling. Curr. Opin. Cell Biol.13, 211–217 (2001). CASPubMed Google Scholar
Reddy, E. P., Korapati, A., Chaturvedi, P. & Rane, S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene19, 2532–2547 (2000). CASPubMed Google Scholar
Levy, D. E. & Darnell, J. E. Jr. Stats: transcriptional control and biological impact. Nature Rev. Mol. Cell Biol.3, 651–662 (2002). CAS Google Scholar
Hirano, T., Ishihara, K. & Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene19, 2548–2556 (2000). CASPubMed Google Scholar
Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J.374, 1–20 (2003). CASPubMedPubMed Central Google Scholar
Silvennoinen, O., Schindler, C., Schlessinger, J. & Levy, D. E. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science261, 1736–1739 (1993). CASPubMed Google Scholar
Zhong, Z., Wen, Z. & Darnell, J. E. Jr Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science264, 95–98 (1994). CASPubMed Google Scholar
Ruff-Jamison, S. et al. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J. Biol. Chem.269, 21933–21935 (1994). CASPubMed Google Scholar
Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature411, 355–365 (2001). CASPubMed Google Scholar
Parsons, J. T. & Parsons, S. J. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr. Opin. Cell Biol.9, 187–192 (1997). CASPubMed Google Scholar
Irby, R. B. & Yeatman, T. J. Role of Src expression and activation in human cancer. Oncogene19, 5636–5642 (2000). CASPubMed Google Scholar
Danial, N. N. & Rothman, P. JAK-STAT signaling activated by Abl oncogenes. Oncogene19, 2523–2531 (2000). CASPubMed Google Scholar
Lin, T. S., Mahajan, S. & Frank, D. A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene19, 2496–2504 (2000). CASPubMed Google Scholar
Yu, C. L. et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science269, 81–83 (1995). First report of persistent activation of STAT3 signalling by an oncoprotein. CASPubMed Google Scholar
Garcia, R. et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ.8, 1267–1276 (1997). CASPubMed Google Scholar
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W. & Darnell, J. E. Jr Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol.18, 2553–2558 (1998). References 34 and 35 provide the first evidence for a requirement of activated STAT3 signalling in cell transformation by an oncoprotein. CASPubMedPubMed Central Google Scholar
Turkson, J. et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol.18, 2545–2552 (1998). CASPubMedPubMed Central Google Scholar
Bromberg, J. F. et al. Stat3 as an oncogene. Cell98, 295–303 (1999). An activated STAT3 mutant provides genetic evidence for the intrinsic oncogenic potential of the STAT3 protein. CASPubMed Google Scholar
Grandis, J. R. et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest.102, 1385–1392 (1998). Demonstration that STAT3 signalling is required for growth of human head and neck cancer cells. CASPubMedPubMed Central Google Scholar
Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity10, 105–115 (1999). The first direct evidence that inhibition of persistent STAT3 signalling in human tumour cells induces apoptosis. CASPubMed Google Scholar
Lou, W., Ni, Z., Dyer, K., Tweardy, D. J. & Gao, A. C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate42, 239–242 (2000). CASPubMed Google Scholar
Mora, L. B. et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res.62, 6659–6666 (2002). CASPubMed Google Scholar
Song, J. I. & Grandis, J. R. STAT signaling in head and neck cancer. Oncogene19, 2489–2495 (2000). CASPubMed Google Scholar
Hung, W. & Elliott, B. Cooperative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. J. Biol. Chem.276, 12395–12403 (2001). CASPubMed Google Scholar
Zhang, Y. W., Wang, L. M., Jove, R. & Vande Woude, G. F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene21, 217–226 (2002). CASPubMed Google Scholar
Garcia, R. et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene20, 2499–2513 (2001). CASPubMed Google Scholar
Niu, G. et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene21, 7001–7010 (2002). CASPubMed Google Scholar
Song, L., Turkson, J., Karras, J. G., Jove, R. & Haura, E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene22, 4150–4165 (2003). CASPubMed Google Scholar
Sriuranpong, V. et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res.63, 2948–2956 (2003). CASPubMed Google Scholar
Xi, S. et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem.278, 31574–31583 (2003). CASPubMed Google Scholar
Frank, D. A. STAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat. Res.115, 267–291 (2003). CASPubMed Google Scholar
Schwaller, J. et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell6, 693–704 (2000). CASPubMed Google Scholar
Huang, M. et al. Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene21, 8804–8816 (2002). CASPubMed Google Scholar
Levis, M. et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood99, 3885–3891 (2002). CASPubMed Google Scholar
Onishi, M. et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol.18, 3871–3879 (1998). CASPubMedPubMed Central Google Scholar
Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D. & Darnell, J. E. Jr Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl Acad. Sci. USA93, 7673–7678 (1996). CASPubMedPubMed Central Google Scholar
Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature410, 1107–1111 (2001). CASPubMed Google Scholar
Catlett-Falcone, R., Dalton, W. S. & Jove, R. STAT proteins as novel targets for cancer therapy. Curr. Opin. Oncol.11, 490–496 (1999). CASPubMed Google Scholar
Turkson, J. & Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene19, 6613–6626 (2000). ArticleCASPubMed Google Scholar
Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M. & Griffin, J. D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood95, 2118–2125 (2000). CASPubMed Google Scholar
Grandis, J. R. et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl Acad. Sci. USA97, 4227–4232 (2000). CASPubMedPubMed Central Google Scholar
Gesbert, F. & Griffin, J. D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood96, 2269–2276 (2000). CASPubMed Google Scholar
Horita, M. et al. Blockade of the Bcr–Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med.191, 977–984 (2000). CASPubMedPubMed Central Google Scholar
Zamo, A. et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene21, 1038–1047 (2002). CASPubMed Google Scholar
Epling-Burnette, P. K. et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest.107, 351–362 (2001). CASPubMedPubMed Central Google Scholar
Aoki, Y., Feldman, G. M. & Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood101, 1535–1542 (2003). CASPubMed Google Scholar
Shen, Y., Devgan, G., Darnell, J. E. Jr & Bromberg, J. F. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl Acad. Sci. USA98, 1543–1548 (2001). CASPubMedPubMed Central Google Scholar
Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol.19, 1–11 (1999). CASPubMedPubMed Central Google Scholar
Prendergast, G. C. Mechanisms of apoptosis by c-Myc. Oncogene18, 2967–2987 (1999). CASPubMed Google Scholar
Bowman, T. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl Acad. Sci. USA98, 7319–7324 (2001). CASPubMedPubMed Central Google Scholar
Ramana, C. V. et al. Regulation of c-myc expression by IFN-γ through Stat1-dependent and-independent pathways. EMBO J.19, 263–272 (2000). CASPubMedPubMed Central Google Scholar
Martino, A., Holmes, J. H., Lord, J. D., Moon, J. J. & Nelson, B. H. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J. Immunol.166, 1723–1729 (2001). CASPubMed Google Scholar
Kijima, T. et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ.13, 355–362 (2002). CASPubMed Google Scholar
Masuda, M. et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res.62, 3351–3355 (2002). CASPubMed Google Scholar
Sinibaldi, D. et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene19, 5419–5427 (2000). CASPubMed Google Scholar
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature408, 307–310 (2000). CASPubMed Google Scholar
Raman, V. et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature405, 974–978 (2000). CASPubMed Google Scholar
Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82, 4–6 (1990). CASPubMed Google Scholar
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86, 353–364 (1996). CASPubMed Google Scholar
Folkman, J. in Cancer Medicine. (eds. Holland, J. F. et al.) 181–204. (Williams and Wilkins, Baltimore, 1997). Google Scholar
Rak, J., Yu, J. L., Klement, G. & Kerbel, R. S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc.5, 24–33 (2000). CASPubMed Google Scholar
Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D. & Johnson, R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res.59, 1592–1598 (1999). CASPubMed Google Scholar
Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature367, 576–579 (1994). CASPubMed Google Scholar
Plate, K. H., Breier, G., Weich, H. A. & Risau, W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature359, 845–848 (1992). CASPubMed Google Scholar
Veikkola, T. & Alitalo, K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol.9, 211–220 (1999). CASPubMed Google Scholar
Veikkola, T., Karkkainen, M., Claesson-Welsh, L. & Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res.60, 203–212 (2000). CASPubMed Google Scholar
Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21, 2000–2008 (2002). First report thatVEGFis a direct target gene of STAT3. CASPubMed Google Scholar
Wei, D. et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene22, 319–329 (2003). CASPubMed Google Scholar
Wei, L. H. et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene22, 1517–1527 (2003). CASPubMed Google Scholar
Semenza, G. L. Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med.41, 79–83 (2002). CASPubMed Google Scholar
Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer3, 721–732 (2003). CAS Google Scholar
Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α. Genes Dev.14, 34–44 (2000). CASPubMedPubMed Central Google Scholar
Bartoli, M. et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J.17, 1562–1564 (2003). CASPubMed Google Scholar
Yahata, Y. et al. Nuclear translocation of phosphorylated STAT3 is essential for VEGF-induced human dermal microvascular endothelial cell migration and tube formation. J. Biol. Chem.278, 40026–40031 (2003). CASPubMed Google Scholar
Deo, D. D. et al. Phosphorylation of Stat-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells: evidence for a dual kinase mechanism. J. Biol. Chem.277, 21237–21245 (2002). CASPubMed Google Scholar
Pardoll, D. M. Spinning molecular immunology into successful immunotherapy. Nature Rev. Immunol.2, 227–238 (2002). CAS Google Scholar
Pardoll, D. M. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol.21, 807–839 (2003). References 94 and 95 provide comprehensive reviews on the current understanding of the mechanisms of tumour immune evasion. CASPubMed Google Scholar
Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity10, 39–49 (1999). CASPubMed Google Scholar
Lee, C. K. et al. Stat3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity17, 63–72 (2002). CASPubMed Google Scholar
Welte, T. et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl Acad. Sci. USA100, 1879–1884 (2003). CASPubMedPubMed Central Google Scholar
Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat3 signaling in tumor cells. Nature Med.10, 48–54 (2004). Demonstration that persistent STAT3 activity in tumour cells suppresses anti-tumour immune responses. PubMed Google Scholar
Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med.2, 1096–1103 (1996). CASPubMed Google Scholar
Yang, A. S. & Lattime, E. C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res.63, 2150–2157 (2003). CASPubMed Google Scholar
Ratta, M. et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood100, 230–237 (2002). CASPubMed Google Scholar
Sombroek, C. C. et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol.168, 4333–4343 (2002). CASPubMed Google Scholar
Nefedova, Y. et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol.172, 464–474 (2004). CASPubMed Google Scholar
Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity19, 425–436 (2003). CASPubMed Google Scholar
Niu, G. et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res.59, 5059–5063 (1999). The first validation of STAT3 as a target for cancer therapy in an animal model. CASPubMed Google Scholar
Niu, G. et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res.61, 3276–3280 (2001). CASPubMed Google Scholar
Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA94, 3801–3804 (1997). CASPubMedPubMed Central Google Scholar
Akira, S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene19, 2607–2611 (2000). CASPubMed Google Scholar
Liu, X. et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev.11, 179–186 (1997). CASPubMed Google Scholar
Socolovsky, M., Fallon, A. E., Wang, S., Brugnara, C. & Lodish, H. F. Fetal anemia and apoptosis of red cell progenitors in Stat5a−/−5b−/− mice: a direct role for Stat5 in Bcl-XL induction. Cell98, 181–191 (1999). CASPubMed Google Scholar
Teglund, S. et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell93, 841–850 (1998). CASPubMed Google Scholar
Battle, T. E. & Frank, D. A. The role of STATs in apoptosis. Curr. Mol. Med.2, 381–392 (2002). CASPubMed Google Scholar
Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem.276, 45443–45455 (2001). Proof of principle that small peptide molecules can disrupt STAT3 dimerization and block cell transformation. CASPubMed Google Scholar
Blaskovich, M. A. et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res.63, 1270–1279 (2003). CASPubMed Google Scholar
Konnikova, L., Kotecki, M., Kruger, M. M. & Cochran, B. H. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer3, 23 (2003). PubMedPubMed Central Google Scholar
Leong, P. et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl Acad. Sci. USA100, 4138–4143 (2003). CASPubMedPubMed Central Google Scholar
Starr, R. & Hilton, D. J. Negative regulation of the JAK/STAT pathway. Bioessays21, 47–52 (1999). CASPubMed Google Scholar
Naka, T., Fujimoto, M. & Kishimoto, T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem. Sci.24, 394–398 (1999). CASPubMed Google Scholar
Shuai, K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene19, 2638–2644 (2000). CASPubMed Google Scholar
Galm, O., Yoshikawa, H., Esteller, M., Osieka, R. & Herman, J. G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood101, 2784–2788 (2003). CASPubMed Google Scholar
Yoshikawa, H. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nature Genet.28, 29–35 (2001). CASPubMed Google Scholar
Chen, C. Y. et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer37, 300–305 (2003). CASPubMed Google Scholar
Zhang, Q. et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol.168, 466–474 (2002). CASPubMed Google Scholar
Turkson, J. et al. Novel peptidomimetic inhibitors of Stat3 dimerization and biological activity. Mol. Cancer Ther. (in the press).
Berg, T. et al. Small-molecular antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA99, 3830–3835 (2002). First example of a small-molecule inhibitor of transcription-factor dimerization that blocks cell transformation. CASPubMedPubMed Central Google Scholar